Hispanic Heritage Month may be coming to a close, but every day we need to ensure people have access to trusted health care information regardless of the language they speak. This time of year, whether you're shopping for health insurance for the first time or looking at your coverage options every year, making sure your health plan meets your needs can be a challenge. That’s why educational resources on health care coverage are important to ensure patients have the information they need and questions to ask to choose the best coverage for them and their family – and to access the treatments and services they need.
To address this, PhRMA’s Access Better Coverage campaign recently launched a Spanish-language hub providing Hispanic Americans with new resources for understanding complicated health insurance terms, what to look for in a health plan and questions to ask your physician.
There are more than 50 million Hispanics living in the United States and in 2013 accounted for nearly one-third of the non-elderly uninsured population. To facilitate dialogue on the importance of access to care for Hispanic Americans, PhRMA asked health experts the following question for our Conversations forum:
What needs to be done to ensure Hispanic patients have access to needed treatments?
Take a look at what they had to say on our Conversations page and check back in a few weeks for our next Conversations series examining a critical aspect of the Medicare program to help low income Americans.
Andrew Powaleny Andrew Powaleny is Director of Public Affairs at PhRMA. Before joining PhRMA in 2015, he worked at the House Energy and Commerce Committee and later as a communications consultant. Andrew came to Washington, D.C. via Connecticut and proudly runs with the DC Front Runners and serves as its co-race director. He is also a member of the National Lesbian Gay Journalists Association and a proud alum of The Fund for American Studies. He’s passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.